南微醫學(688029.SH):微創諮詢減持數過半 已減持1.76%股份、中科招商被動成為公司第一大股東
格隆匯9月30日丨南微醫學(688029.SH)公佈,公司於2022年9月30日收到微創諮詢的吿知函,2022年9月7日至2022年9月29日,微創諮詢通過集中競價交易方式累計減持公司股份數量1,197,844股,通過大宗交易方式減持公司股份數量2,095,200股,合計329.3044萬股,佔公司總股本的1.7587%。此次減持計劃數量已經過半,減持計劃尚未實施完畢。
此次權益變動後,信息披露義務人微創諮詢持有公司股份數量從43,067,360股減少至39,774,316股,持股比例從23.0004%減少至21.2417%,持股比例減少1.7587%。微創諮詢及其一致行動人隆曉輝先生合計持股比例從24.0554%減少至22.2967%。
此次權益變動前,深圳市中科招商創業投資有限公司(簡稱“中科招商”)持有公司股份42,251,300股,佔公司總股本比例22.5646%,為公司第二大股東。此次微創諮詢權益變動後,因中科招商未發生權益變動,中科招商被動成為公司第一大股東。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.